CoMind
Focus: CoMind develops non-invasive brain monitoring systems focused on neurology applications, currently in early feasibility stages with a single active trial.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$102.5M
Open Jobs
10-1 this month
Stable — net -1 jobs in 30d
3 added, 4 removed. Backfill posture.
Should You Work at CoMind?
AI assessmentCoMind offers early-stage neurotech opportunity with meaningful upside, but significant execution risk and limited near-term catalysts make it suitable only for risk-tolerant candidates seeking frontier innovation over near-term stability.
Why Work Here
- Early-stage neurotech company with focused pipeline in high-need intracranial pressure monitoring space
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
CoMind Early Feasibility Study
Intracranial PressureClinical Trials (1)
NCT06368648CoMind Early Feasibility Study
N/AHelp build intelligence for CoMind
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.